ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional

JSP191 Antibody Targeting Conditioning in SCID Patients

ClinicalTrials.gov ID: NCT02963064

Public ClinicalTrials.gov record NCT02963064. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of JSP191 for Hematopoietic Cell Transplantation Conditioning to Achieve Engraftment and Immune Reconstitution in Subjects With SCID

Study identification

NCT ID
NCT02963064
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Enrollment
23 participants

Conditions and interventions

Conditions

Interventions

  • Humanized anti-CD117 Monoclonal Antibody (JSP191) Biological

Biological

Eligibility (public fields only)

Age range
3 Months to 12 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 19, 2017
Primary completion
Jul 6, 2025
Completion
Jul 6, 2025
Last update posted
Jul 27, 2025

2017 – 2025

United States locations

U.S. sites
9
U.S. states
7
U.S. cities
9
Facility City State ZIP Site status
UCLA Mattel Children's Hospital Los Angeles California 90095
Lucile Packard Children's Hospital Palo Alto California 94304
UCSF Benioff's Children's Hospital San Francisco California 94158
Children's National Medical Center Washington D.C. District of Columbia 20010
Children's Healthcare of Atlanta Atlanta Georgia 30322
National Institutes of Health Clinical Center Bethesda Maryland 20892
University of Minnesota Minneapolis Minnesota 55455
Memorial Sloan Kettering Cancer Center New York New York 10065
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02963064, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 27, 2025 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02963064 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →